Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies

Friday, July 28, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

The agreement is the first to apply value-based contracts to cover Medicaid patients in the United States.

SAN JUAN, Puerto Rico, July 28, 2017 /PRNewswire/ -- Abarca Health, a pharmacy benefit management (PBM) and technology

company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (NASDAQ: BIIB) for select products in Biogen's leading multiple sclerosis (MS) portfolio. This first-of-its-kind agreement between the companies offers an innovative approach to connecting outcomes with the effective net cost of the products. The agreement places accountability on Biogen to deliver safety, efficacy, and value for the patients who receive these life-impacting therapies and for the payers who finance them.

"We are excited to partner with Biogen in implementing this innovative, data-driven, and outcomes-based pricing program for MS drug therapies.  We believe this program is a significant milestone in our efforts to collaborate with pharmaceutical manufacturers to find a better way to guide patients and payers down the path to value, especially in high impact disease categories," stated Javier Gonzalez, Chief Operating Officer of Abarca Health.

This contract builds on Abarca Health's ongoing work with Biogen to find better ways to collaborate in the treatment of patients afflicted with complex, high-cost conditions.

"We believe that contracting approaches like this will help expand access for patients. We are excited to work with an innovative partner like Abarca Health and lead the way for MS care," said Jean-Paul Kress, Executive Vice President and President, International and Head of Global Therapeutic Operations of Biogen.

Outcomes-based contracting is an important part of the future of healthcare. By partnering with manufacturers such as Biogen, Abarca Health is ensuring greater accountability around the investments made by payers and patients in high cost treatments, which leads to better access and better outcomes for patients.

About ABARCA HEALTH

As a pharmacy benefit management and technology company, Abarca Health serves more than 2 million people across the nation helping its clients manage over $1 billion per year in pharmaceutical spending. The company leverages its people, culture and technology to develop deep partnerships with health plans, government programs, self-insuring employer/union groups, and other payers - partnerships that are both authentic and flexible. By building trust with and delivering consistently for its customers, Abarca is able to better work together to create a healthcare experience that cares for us like family, guides us on the path to value, and inspires us to live better every day. For more information, please visit www.abarcahealth.com.

View original content:http://www.prnewswire.com/news-releases/abarca-health-announces-innovative-value-based-contract-with-biogen-for-multiple-sclerosis-therapies-300495968.html

SOURCE Abarca Health



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook